Why Infinera, Geron, and Alexion Pharmaceuticals Are Today's 3 Best Stocks

The S&P 500 advances by better than 1% while Infinera, Geron, and Alexion Pharmaceuticals all rocket higher by at least 21%!

Jan 30, 2014 at 5:15PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Sometimes the oddest news can move the broad-based S&P 500 (SNPINDEX:^GSPC), and today was one such day!

With strong earnings very much in the forefront, investors instead turned to important economic indicators to push the S&P 500 more than 1% to the upside. Specifically, investors focused on the weekly initial jobless claims and the preliminary estimate for fourth-quarter GDP.

Here's the kicker: both figures were weak or weaker than expected. Weekly initial jobless claims rose 19,000 from the prior week to a seasonally adjusted 348,000, while the first fourth-quarter GDP estimate of 3.2% growth is well below the 4.1% GDP growth reported in the third quarter. Under normal circumstances you'd think the market would be lower on this news, but it presents the perfect case scenario for the Federal Reserve to scale back on easing of its economic stimulus. The Fed has cut $20 billion from its original $85 billion monthly bond purchases over a two-meeting stretch, so this could be the precursor to keep its stimulus at $65 billion per month in the interim.

A slew of positive earnings reports, as well as the above economic data, pushed the S&P 500 higher at day's end by 19.99 points (1.13%) to close at 1,794.19.

Leading the market to the upside today was optical networking equipment provider Infinera (NASDAQ:INFN), which gained 29% after reporting better than expected fourth-quarter earnings results. For the quarter, Infinera saw an 8.6% increase in total revenue to $139.1 million as its bottom line improved from a year-ago loss of $0.05 per share to breakeven. By comparison, Wall Street had expected Infinera to deliver a $0.02 loss per share on $136.2 million in revenue. Most importantly, gross margin improved 5% to 41%. Although Infinera is a bit pricey at 29 times forward earnings, the trickle down from telecom service providers expanding their infrastructure should give Infinera a decent chance at continuing its run higher.

Shares of Geron (NASDAQ:GERN) oddly rocketed higher by 23.6% after the clinical-stage biopharmaceutical company disclosed the sale of 22.5 million common shares for $4 per share. The intended $90 million raise will be used to fund the company's midstage trial of imetelstat to treat myelofibrosis, as well as for general corporate purposes. While I can understand investors' excitement with having fresh funding, the simple fact that Geron is about to dilute shareholders by 17.4% certainly doesn't make me feel comfortable about today's rally. In addition, finding out earlier this week that the Mayo Clinic had ended enrollment in its investigator-sponsored trial of imetelstat, and that 20 of 79 patients discontinued the study, is a bit worrisome.

Finally, biopharmaceutical giant Alexion Pharmaceuticals (NASDAQ:ALXN) advanced 21.1% after it, too, reported market-topping fourth-quarter results. For the quarter, Alexion delivered a 38% increase in Soliris sales ($441.9 million) as earnings per share climbed 45% to $0.87. Comparatively speaking, the Street only expected Alexion to report $430.7 million in revenue on $0.83 in EPS. Furthermore, Alexion provided full-year guidance of $2 billion-$2.02 billion in sales and EPS of $3.70-$3.80, which was boosted by a reduced effective tax rate expectation of 10%-11%. While it's hard to deny that Soliris has turned into an impressive growth drug, it's also really difficult to support Alexion's valuation at nearly 16 times this year's sales and with only one FDA-approved drug.

Tired of not seeing your stocks among the days best gainers? Perhaps you aren't thinking far enough outside the box!
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool owns shares of, and recommends Infinera. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers